Metraipolis › archive › dc_c697b13ce6dc

Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial — Europe PMC PMID:41967085

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41967085
DOI: 10.1093/eschf/xvag104
License (as archived): solo-consultazione
Archived: 2026-11-02T20:06:25.081Z
SHA-256 of the archived text: de7af086f68829b518d3833931743fec5982ad36922a788433438d8946e25c0a
Stable URL of this page: https://metraipolis.com/documento/dc_c697b13ce6dc

How to cite

Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial — Europe PMC PMID:41967085 — Europe PMC (en), https://europepmc.org/article/MED/41967085 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c697b13ce6dc (Metraipolis archive dc_c697b13ce6dc, sha256 de7af086f68829b518d3833931743fec5982ad36922a788433438d8946e25c0a)

BibTeX

@misc{dcc697b13ce6dc,
  title = {Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial — Europe PMC PMID:41967085},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41967085},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c697b13ce6dc; sha256 de7af086f68829b518d3833931743fec5982ad36922a788433438d8946e25c0a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41967085. Agents can read the archived copy with the MCP tool read_document.